Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Sym021 |
Trade Name | |
Synonyms | Sym-021|Sym 021 |
Drug Descriptions |
Sym021 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3822, PMID: 31046547, PMID: 31754392). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
CAS Registry Number | 2233593-42-3 |
NCIT ID | C142865 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Futuximab + S095029 + Sym021 | Futuximab S095029 Sym021 | 0 | 1 |
Modotuximab + S095029 + Sym021 | Modotuximab S095029 Sym021 | 0 | 1 |
S095029 + Sym021 | S095029 Sym021 | 0 | 1 |
Sym021 | Sym021 | 0 | 1 |
Sym021 + Sym022 | Sym021 Sym022 | 0 | 1 |
Sym021 + Sym023 | Sym021 Sym023 | 0 | 1 |
Sym021 + Sym024 | Sym021 Sym024 | 0 | 1 |